/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Calidi Biotherapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.5 0.049(4.9%) CLDI at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 1.39
Highest Today 1.5
Today’s Open 1.44
Prev. Close 1.43
52 Week High 26.04
52 Week Low 1.10
Day’s Range: Low 1.39 High 1.5
52-Week Range: Low 1.10 High 26.04
1 day return -
1 Week return -2.94
1 month return -1.0
3 month return -7.76
6 month return +318.19
1 year return -24.61
3 year return -85.31
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 10.25 M

PB Ratio 1.5645

PE Ratio 4.0857

Enterprise Value 3.76 M

Total Assets 14.18 M

Volume 101994

Company Financials

Annual Revenue FY23:0 0.0M, FY21:449000 0.4M, FY20:0 0.0M

Annual Profit FY23:0 0.0M, FY21:355000 0.4M, FY20:0 0.0M

Annual Net worth FY23:-29216000 -29.2M, FY21:-10933000 -10.9M, FY20:-7937000 -7.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-427000 -0.4M, Q2/2025:-407000 -0.4M, Q1/2025:-394000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-378000 -0.4M

Quarterly Net worth Q3/2025:-5149000 -5.1M, Q2/2025:-5715000 -5.7M, Q1/2025:-4986000 -5.0M, Q3/2024:-5054000 -5.1M, Q2/2024:-5767000 -5.8M

Fund house & investment objective

Company Information Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 28

Industry Biotechnology

CEO Dr. Eric E. Poma Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow